Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo‐controlled trial in breast cancer patients (TRANSDERMIS trial)

Robijns, Jolien; Censabella, Sandrine; Bollen, Heleen; Pannekoeke, Luc; Bussé, Lore; Colson, Dora; Kaminski, Iris; Bulens, Paul; Maes, André; Noé, Leen; Brosens, Marc; Timmermans, Annick; Lambrichts, Ivo; Somers, Veerle; Mebis, Jeroen

doi:10.1002/lsm.22804

Cited by 45 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In dermatology, applications of PBM span a very wide range of conditions including wound healing, hair regrowth, treatment of psoriasis and others [1][2][3][4][5][6][7]. While the commercialization of devices based on PBM has been progressing at a very fast pace over the past years, the field still lacks significant consensus about fundamental mechanisms of PBM, including the molecular targets of light and the optimal selection of optical treatment parameters [2,3].…”

mentioning

confidence: 99%

Differential response of human dermal fibroblast subpopulations to visible and near‐infrared light: Potential of photobiomodulation for addressing cutaneous conditions

et al. 2018

View full text Add to dashboard Cite

This study highlights a differential impact of light on human skin cells with upregulation of metabolic activity with NIR light, and inhibition of pro-collagen production and proliferation in response to blue light. These findings open-up new avenues for developing therapies for different cutaneous conditions (e.g., treatment of keloids and fibrosis) or differential therapy at distinct stages of wound healing. Lasers Surg. Med. 50:859-882, 2018. © 2018 Wiley Periodicals, Inc.

show abstract

mentioning

confidence: 99%

Differential response of human dermal fibroblast subpopulations to visible and near‐infrared light: Potential of photobiomodulation for addressing cutaneous conditions

et al. 2018

View full text Add to dashboard Cite

show abstract

“…PBM was applied from the first until the last day of RT (2Â/ week, 14 sessions) by a trained operator using the class IV MLS Ò M6 laser (ASA Srl, Vicenza, Italy) [17]. This device is commercially available, built in compliance with EC/EU rules, received FDA approval, and is CE certified.…”

Section: Photobiomodulationmentioning

confidence: 99%

Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)

Robijns

Lodewijckx

Bollen

et al. 2021

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

Background and purpose: The purpose of this study was to investigate the effectiveness of photobiomodulation therapy (PBMT) for the prevention of acute radiation dermatitis (ARD) in head and neck cancer (HNC) patients. Materials and methods: A randomised, placebo-controlled trial (RCT) with 46 HNC patients who underwent radiotherapy (RT) with or without concomitant chemotherapy was set up (DERMISHEAD trial). Patients were randomised to receive PBM or placebo treatments from the first day of RT (2Â/week) alongside the institutional skincare. The severity of skin reactions was assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v4.03) and the Radiotherapy-Induced Skin Reaction Assessment Scale (RISRAS). Quality of life (QoL) was evaluated using the Skindex-16 questionnaire. Results: PBMT significantly reduced NCI-CTCAE grade 2-3 ARD with 49% at the end of RT. Conclusion:The results of the first RCT in HNC patients showed that PBMT is an effective method to prevent the development of severe ARD. These results support the implementation of PBM in the clinical oncology -radiotherapy practice.

show abstract

“…29 Over the last 20 years, PBMT has become a new treatment modality within supportive cancer care (e.g., oral mucositis and radiodermatitis). [29][30][31][32][33][34][35] The principal chromophores for PBMT are located inside the mitochondria. As a result, cells with a large number of mitochondria, such as muscle cells and neurons, are particularly sensitive to this therapy.…”

Section: Current Treatment Strategiesmentioning

confidence: 99%

Photobiomodulation Therapy for the Management of Chemotherapy-Induced Peripheral Neuropathy: An Overview

Lodewijckx

Robijns

Bensadoun

et al. 2020

Photobiomodulation, Photomedicine, and Laser Surgery

Self Cite

View full text Add to dashboard Cite

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy (CT), affecting 68% of patients. Current treatment strategies are based on pharmacological symptom management, but have limited results. Photobiomodulation therapy (PBMT) is a new and emerging therapeutic tool in the supportive care of cancer patients. In this overview, we explore the usability of PBMT for management of CIPN.Objective: To provide a comprehensive overview of management of CIPN with PBMT. Methods: Specific terms, including ''Photobiomodulation Therapy,'' ''Drug Therapy,'' and ''Peripheral Nervous System Diseases,'' were identified for the literature research in PubMed. Results: Three articles were considered eligible for this review. Primary outcome measures were highly variable across the included studies. Conclusions: PBMT might be an effective treatment strategy to manage CIPN, with very encouraging reports from renowned teams, but evidence is limited. More methodologically uniform research (mainly regarding the parameters of PBMT) is needed to support the use of PBMT for this indication.

show abstract

Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo‐controlled trial in breast cancer patients (TRANSDERMIS trial)

Abstract: The results of this trial show that PBMT is an effective tool to prevent the development of grade 2 acute RD or higher in BC patients. In addition, it also reduces the patients' symptoms related to RD. Lasers Surg. Med. © 2018 Wiley Periodicals, Inc.

Cited by 45 publications

References 41 publications

Differential response of human dermal fibroblast subpopulations to visible and near‐infrared light: Potential of photobiomodulation for addressing cutaneous conditions

Differential response of human dermal fibroblast subpopulations to visible and near‐infrared light: Potential of photobiomodulation for addressing cutaneous conditions

Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)

Photobiomodulation Therapy for the Management of Chemotherapy-Induced Peripheral Neuropathy: An Overview

Contact Info

Product

Resources

About